David J. Mangelsdorf
Team Member @ Ligand Pharmaceuticals
David J. Mangelsdorf is a startup investor at Ligand Pharmaceuticals. David J. Mangelsdorf, PhD, has been Professor and Chair of the Department of Pharmacology at the University of Texas Southwestern Medical Center at Dallas since 1993. He holds the Beatrice and Miguel Elias Distinguished Chair in Biomedical Science. His research is focused on the mechanism of action of nuclear receptors and the characterization oftheir ligand activities. His work has led to the therapeutic targeting of nuclear receptors for diseases such as atherosclerosis, cholestasis, type 2 diabetes, and cancer. He has been involved in the start-up of several biotech companies, including Ligand Pharmaceuticals and X-Ceptor Therapeutics. He completed postdoctoral studies at the Salk Institute for Biological Sciences after receiving a PhD in biochemistry from the University of Arizona in Tucson. He is a member of the National Academy of Sciences and an Investigator of the Howard Hughes Medical Institute.
Last updated:
For AI agents: llms.txt
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Ligand business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporatecost structure. Ligand's goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified, and lower-risk business than a typical biotech company. Ligand business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation, and partnering. Ligand partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management, and commercialization) to ultimately generate Ligand revenue.
Ligand Pharmaceuticals Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Bob Chen
Director, Systems Engineering and Site Head
|
|||
|
David J. Mangelsdorf
Team Member
|
|||
John Higgins
CEO
|
|||
Richard Baxter
Senior Vice President of Investment Operations
|
|||
Todd C. Davis
Chief Executive Officer & Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
FAQ
How do I contact David J. Mangelsdorf?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
